Dr. Betts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
909 Fulton St SE
Minneapolis, MN 55455Phone+1 612-672-7422
Summary
- Dr. Brian Betts is a hematologist in Minneapolis, MN and is affiliated with University of Minnesota. He received his medical degree from Eastern Virginia Medical School and has been in practice 16 years. He specializes in hematologic oncology and is experienced in graft-versus-host disease, stem cell transplantation, leukemia, and cell therapy.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of MinnesotaResidency, Internal Medicine, 2004 - 2007
Eastern Virginia Medical SchoolClass of 2004
Certifications & Licensure
NY State Medical License 2008 - 2025
MN State Medical License 2018 - 2024
FL State Medical License 2011 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.Joseph Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao
Blood. 2024-11-28 - Novel Scoring System for Ranking Hematopoietic Stem Cell Transplantation.Lee Ann Baxter-Lowe, Tao Wang, Michelle Kuxhausen, Stephen R Spellman, Martin Maiers
Clinical Transplantation. 2024-11-01 - Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients ...Megan M Herr, Sophia R Balderman, Paul K Wallace, Yali Zhang, Joseph D Tario Jr
Transplantation and Cellular Therapy. 2024-08-01
Press Mentions
Tandem 2025: Roswell Park Team Creates Predictive Model to Inform Care of Lymphoma PatientsFebruary 3rd, 2025- Pacritinib with Sirolimus/Tacrolimus Does Not Prevent Acute GVHDAugust 28th, 2024
- VITRAC Therapeutics Initiates a Phase 1/2 Clinical Trial with the Aurora Kinase a Inhibitor VIC-1911 in GVHD ProphylaxisApril 26th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
